AIMIA TO REPORT FOURTH QUARTER AND FULL-YEAR 2024 RESULTS ON MARCH 28
Werte in diesem Artikel
TORONTO, March 11, 2025 /CNW/ - Aimia Inc. (TSX: AIM) will announce its fourth quarter and full-year financial results for the period ended December 31, 2024 on Friday, March 28, 2025.
Aimia's financial results are expected to be released at approximately 7:00 am ET followed by a live presentation by management via a webcast and teleconference call at 8:30 am ET the same day.
Aimia Q4 Earnings Conference Call/Webcast
- Time: 8:30m ET
- Date: March 28, 2025
- The presentation will be available in a listen-only mode via:
- Telephone at 1-888-699-1199 (North America) or 416-945-7677 (internationally)
- Webcast at https://app.webinar.net/MmPwKJ49k0R
- Presentation materials to be referenced during the call will be available from the Company's website at https://www.aimia.com/investor-relations/events-presentations/
- Listeners are encouraged to dial-in/log-in 15 minutes prior to start of the presentation to secure a line or test their connection.
An archive of the Aimia's Q4 earnings presentation will be available from the Company's website.
About Aimia
Aimia Inc. (TSX: AIM) is a diversified company focused on unlocking the growth potential of its two global businesses, Bozzetto, a sustainable specialty chemicals company, and Cortland International, a rope and netting solutions company. Headquartered in Toronto, Aimia's priorities include monetizing its non-core investments, returning capital to its shareholders, and efficiently utilizing its loss carry-forwards to create shareholder value.
For more information about Aimia, visit www.aimia.com.
SOURCE Aimia Inc.
Übrigens: Hemispherx Biopharma und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Hemispherx Biopharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hemispherx Biopharma
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Hemispherx Biopharma Inc Registered Shs
Analysen zu Hemispherx Biopharma Inc Registered Shs
Keine Analysen gefunden.